Intellia Therapeutics (NASDAQ:NTLA) Given “Neutral” Rating at JPMorgan Chase & Co.

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reiterated by research analysts at JPMorgan Chase & Co. in a note issued to investors on Friday. They presently have a $13.00 price target on the stock, down from their prior price target of $45.00. JPMorgan Chase & Co.‘s price target indicates a potential upside of 19.71% from the stock’s current price.

Several other research analysts have also recently weighed in on the stock. Barclays decreased their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Canaccord Genuity Group reiterated a “buy” rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Wedbush reissued a “neutral” rating and set a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. The Goldman Sachs Group cut their target price on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, January 14th. Finally, BMO Capital Markets decreased their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.06.

Intellia Therapeutics Trading Up 0.6 %

Shares of Intellia Therapeutics stock opened at $10.86 on Friday. The company’s 50-day moving average price is $10.90 and its 200-day moving average price is $15.72. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -2.00 and a beta of 1.80. Intellia Therapeutics has a 12-month low of $8.96 and a 12-month high of $34.87.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 29,000 shares of company stock valued at $352,551. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. ARK Investment Management LLC boosted its stake in Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after purchasing an additional 280,946 shares in the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock valued at $118,816,000 after buying an additional 562,249 shares during the period. State Street Corp grew its position in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after acquiring an additional 780,754 shares during the period. Regeneron Pharmaceuticals Inc. bought a new position in Intellia Therapeutics in the 4th quarter worth $43,177,000. Finally, Geode Capital Management LLC lifted its position in Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock valued at $27,865,000 after purchasing an additional 45,930 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.